Combination treatments with PARP inhibitors, such as veliparib, talazoparib, rucaparib, olaparib, and niraparib, which, with the exception of veliparib, are approved as targeted drugs for BRCA-mutated cancer treatment8,27, demonstrated the highest synergy with ATM and ATR inhibitors across multiple cancer types. This evidence concerns the gene ATM and cancer.